Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing clinical study of group A and C meningococcal polysaccharide conjugate vaccine (Yuxi Walvax)
ChiCTR2000039054Phase 4Recruiting
- Sponsor
- Shanxi Center for Disease Control and Prevention
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of meningococcal group A and C polysaccharide conjugate vaccine in meningococcal disease and Serogroup C meningococcal disease (MenC) (4 arms), sponsored by Shanxi Center for Disease Control and Prevention. Primary endpoint: Serum bactericidal antibody titers (rSBA) against meningococcal serogroups A and C before and after immunization. Started Jul 2020; status: recruiting.
02
Drugs
meningococcal group A and C polysaccharide conjugate vaccine
03
Conditions
meningococcal diseaseSerogroup C meningococcal disease (MenC)
Beyond the preview
Go deeper on ChiCTR2000039054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039054.